ResMed Q4 2024 Adj. EPS $2.08 Beats $2.07 Estimate, Sales $1.232B Beat $1.217B Estimate
Portfolio Pulse from Benzinga Newsdesk
ResMed (NYSE:RMD) reported Q4 2024 adjusted EPS of $2.08, beating the $2.07 estimate. Sales were $1.232 billion, surpassing the $1.217 billion estimate and marking a 9.80% increase from the same period last year.
August 01, 2024 | 8:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ResMed reported Q4 2024 adjusted EPS of $2.08, slightly beating the $2.07 estimate. Sales were $1.232 billion, exceeding the $1.217 billion estimate and showing a 9.80% year-over-year increase.
ResMed's Q4 2024 earnings and sales both exceeded analyst estimates, indicating strong financial performance. The year-over-year sales growth of 9.80% further supports a positive outlook for the stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100